A mitochondria-targeted peptide that stabilizes cardiolipin and restores mitochondrial function — in clinical trials.
SS-31 (elamipretide) is a tetrapeptide with an unusual mitochondria-targeting mechanism. It is a Szeto-Schiller peptide — a class of cell-permeable peptides that selectively concentrate in the inner mitochondrial membrane. There, it binds to cardiolipin, a phospholipid essential for the structural integrity and function of the electron transport chain.
Cardiolipin is uniquely present in mitochondrial membranes and is critical for efficient ATP production. With aging and in disease states (heart failure, metabolic disease), cardiolipin becomes oxidized and loses its ability to properly organize the electron transport chain complexes. SS-31 stabilizes cardiolipin, restoring mitochondrial cristae structure and electron transport efficiency.
This mechanism makes SS-31 one of the few compounds that directly targets mitochondrial dysfunction — the underlying cause of many age-related diseases and energy-related conditions. Unlike antioxidants that simply scavenge free radicals, SS-31 addresses the structural cause of mitochondrial dysfunction.
SS-31 has received FDA Orphan Drug Designation for Barth syndrome (a rare genetic disease causing cardiolipin deficiency and heart failure). Clinical trials in Barth syndrome and heart failure have shown safety and some functional improvements. The EMBRACE heart failure trial showed improvements in exercise capacity. Phase 2/3 trials for various indications are ongoing.
Preclinical research across multiple species demonstrates remarkable results: improved cardiac function after heart attack, reversal of age-related kidney decline, prevention of muscle atrophy, protection in neurodegenerative disease models, and reversal of age-related metabolic dysfunction. The breadth of benefit in aging-related conditions is exceptionally broad.
📚 Key Reference: PMID: 24721453 (SS-31 Barth syndrome), PMID: 25053788 (heart failure preclinical)
Clinical trial data to date shows good tolerability. Injection site reactions are the primary side effect. As an endogenous-pathway compound (targeting existing mitochondrial structures), the safety profile appears favorable. Full long-term safety profile is still being established. Consult your provider.
Orphan Drug Designation from FDA for Barth syndrome. In Phase 2/3 clinical trials for heart failure and other conditions. Not FDA-approved for routine use. Available through specialized compounding pharmacies. One of the more scientifically credible longevity peptides due to clinical trial pathway.